Preclinical efficacy of a novel dual PI3K/mTOR inhibitor, CMG002, alone and in combination with sorafenib in hepatocellular carcinoma
Crossref DOI link: https://doi.org/10.1007/s00280-019-03918-y
Published Online: 2019-08-05
Published Print: 2019-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kim, Mi Na http://orcid.org/0000-0001-5381-230X
Lee, Seung Min
Kim, Jin Sung
Hwang, Seong Gyu
Text and Data Mining valid from 2019-08-05
Version of Record valid from 2019-08-05
Article History
Received: 27 February 2019
Accepted: 29 July 2019
First Online: 5 August 2019
Compliance with ethical standards
:
: Nothing to declare for all authors.